Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01806077 · ClinicalTrials.gov registry record · Phase 1
Safety Study of PZ-128 in Subjects With Multiple Coronary Artery Disease Risk Factors
A Phase 1 study, sponsored by Tufts Medical Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 32
- Enrollment target
NCT01806077 is a Phase 1 study that has completed, run by Tufts Medical Center. The registered enrollment target is 32 participants.
The verdict
NCT01806077, a Phase 1 study, has completed, sponsored by Tufts Medical Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 32 participants
- Enrollment target
Study Summary
This study is a Phase I, intravenous, single-dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PZ-128 (pepducin inhibitor of PAR1) in subjects with vascular disease or who have 2 or more coronary artery disease (CAD) risk factors.
Interventions
- DRUG PZ-128
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2013-04 |
| Est. Completion | 2014-11 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01806077
The ClinicalTrials.gov registry entry for NCT01806077 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tufts Medical Center, which has 169 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which PZ-128 is the first listed.
NCT01806077 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01806077 about?
NCT01806077 is a clinical study titled "Safety Study of PZ-128 in Subjects With Multiple Coronary Artery Disease Risk Factors". This study is a Phase I, intravenous, single-dose escalation study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of PZ-128 (pepducin inhibitor of PAR1) in subjects with vascular disease or who have 2 or more coronary artery disease (CAD) risk factors.
What is the current status of trial NCT01806077?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 32 participants. The study started on 2013-04. Estimated completion is 2014-11.
What interventions are being tested in trial NCT01806077?
The interventions under investigation include: PZ-128 (DRUG).
Who is sponsoring clinical trial NCT01806077?
This trial is sponsored by Tufts Medical Center, which has 169 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.